<DOC>
	<DOCNO>NCT00597623</DOCNO>
	<brief_summary>Digital osteoarthritis ( DO ) affect interphalangeal joint Metacarpophalangeal ( MCP ) thumb common disease , prevalence increase age ( 36 % population age 70 ) . Certain form DO clinical manifestation involve inflammatory feature particularly refractory usual treatment ( analgesic , NSAIDs , brace local injection ) . The mechanism osteoarthritis involve two major cytokine : interleukin-1 beta tumor necrosis factor alpha . TNF alpha particularly involved inflammation process . The aim present study study efficacy TNF alpha blocker ( 2 injection adalimumab compare placebo injection patient severe refractory hand osteoarthritis . We hope new therapeutic option may induce substantial pain relief .</brief_summary>
	<brief_title>Efficacy Study Anti-Tumor Necrosis Factor ( TNF ) Alpha Agent Patients With Hand Osteoarthritis</brief_title>
	<detailed_description>Objective : To demonstrate efficacy two subcutaneous injection anti-TNF alpha ( adalimumab ) patient DO refractory usual treatment ( NSAIDs - analgesic ) . Design : Randomized placebo-controlled multicenter ( 20 site ( amendment 18/12/2008 ) ) trial Trial duration : 6 month follow-up per patient , total trial duration : 12 month Number patient : 84 ( ) Dose administration : Two subcutaneous injection separate 2-week interval either adalimumab placebo . Therapeutic precaution inherent prescription anti-TNF alpha base upon recommend rheumatoid arthritis . With two injection anti-TNF alpha , risk complication ( infectious particular ) inherent anti-TNF alpha appear extremely slight . Patient selection : Patients digital osteoarthritis ( DIP PIP ) accord American College Rheumatology ( ACR ) criterion ( recent X-ray , less 6 month , hand , show sign digital osteoarthritis ) , symptomatic 3 month ( least three finger joint ) score 40 mm pain visual analog scale ( VAS ) despite use level 1 analgesic ( acetaminophen : 4 g daily ) andNSAIDs . Main Exclusion criterion contraindication anti-TNF alpha accord international guideline . Methods : Patients see screen visit , treatment administration ( W0 W2 ) follow-up visit : W6 , 10 , 14 26 . NSAIDs stop time screen . Efficacy evaluation : The efficacy endpoint improvement pain pain VAS different time assessment ( primary endpoint W6 ) . A 50 % improvement , comparison baseline , consider significant . Secondary endpoint : number tender joint , number swollen joint , morning stiffness , global assessment handicap patient , global assessment handicap physician , DREISER 'S algofunctional index , Cochin hand index , weekly evolution pain ( patient record ) , record analgesic use ( acetaminophen NSAIDs ) . Statistical data : Statistical analysis perform inter-group difference intention-to-treat population . khi-2 use criterion number 1 . Anticipated result : Significant superiority adalimumab placebo would provide therapeutic solution difficult-to-treat patient hand OA .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Age : 4080 Men woman Digital osteoarthritis ( DIP PIP ) accord ACR criterion ( recent Xray , date less 6 month , hand show radiological sign digital osteoarthritis ) Symptomatic digital osteoarthritis 3 month ( least every day ) despite take analgesic NSAIDs ( except contraindication latter therapeutic group ) Osteoarthritis affect three finger joint Pain 40 mm evaluate pain VAS ( 0100 mm ) No contraindication antiTNF alpha treatment No digital osteoarthritis surgery schedule within next 2 month Written inform consent Pregnant woman woman reproductive potential without effective contraception Known hypersensitivity Patients already treat antiTNF alpha Finger osteoarthritis secondary inflammatory rheumatism Psoriasis Existence painful syndrome upper limb likely interfere monitor pain ( cervicobrachial neuralgia , incapacitate carpal tunnel syndrome , joint disorder elbow shoulder ) Inflammatory rheumatism Contraindications antiTNF alpha agent : patient suspect reactivation tuberculosis ( phlyctenular IDR , past history tuberculosis , chest Xray deem suspect ) know leukopenia ( &lt; 3500 leukocyte ) , know hepatic cytolysis ( transaminases twice normal ) , history serious allergy , concomitant infection , past history serious systemic infection ( septicemia ) , history know cancer within past 5 year , history multiple sclerosis Skin disease incompatible subcutaneous injection Anticoagulant ( oral ) treatment heparin curative dose Surgery schedule within come 2 month Finger surgery schedule within come 6 month Local injection corticosteroid symptomatic finger joint previous month Local injection hyaluronic acid symptomatic finger joint prior 3 month Treatment slowacting antiosteoarthritis agent initiate colchicine ( amendment 26/06/2008 ) within previous 3 month Oral corticosteroid Psychiatric illness Noncontrolled diabetes `` mellitus '' Known viral hepatitis B C , HIV infection</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Osteoarthritis</keyword>
	<keyword>Hand</keyword>
	<keyword>Tumor Necrosis Factor-alpha inhibitor</keyword>
	<keyword>Biological Therapy</keyword>
</DOC>